E-Capro
Generic Name
Epsilon-aminocaproic Acid
Manufacturer
Generic Pharmaceutical Company
Country
Global
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| e capro 1 gm injection | ৳ 35.00 | N/A |
Description
Overview of the medicine
Epsilon-aminocaproic acid (EACA) is a synthetic amino acid that acts as an antifibrinolytic agent. It is used to treat or prevent excessive bleeding in various clinical situations by inhibiting the breakdown of blood clots.
Uses & Indications
Dosage
Adults
Initial loading dose of 4-5 grams by intravenous infusion over 1 hour, followed by a continuous infusion of 1-1.25 grams per hour, or intermittent doses as directed by a physician.
Elderly
Use with caution; dosage adjustment may be necessary due to potential age-related decrease in renal function. Monitor renal function closely.
Renal_impairment
Dose reduction is necessary in patients with renal impairment due to the drug's primary renal excretion. Contraindicated in severe renal impairment.
How to Take
Administer intravenously, typically diluted in a compatible solution such as Normal Saline or Dextrose 5% in water. Administer slowly to avoid hypotension, bradycardia, and/or arrhythmia.
Mechanism of Action
Epsilon-aminocaproic acid inhibits fibrinolysis by competitively inhibiting the activation of plasminogen to plasmin and, to a lesser extent, by inhibiting plasmin itself. This action helps to stabilize blood clots and prevent excessive bleeding.
Pharmacokinetics
Onset
Within minutes of intravenous administration.
Excretion
Mainly excreted unchanged in the urine by glomerular filtration and tubular secretion.
Half life
Approximately 1-2 hours.
Absorption
For intravenous administration, EACA is immediately bioavailable. Peak plasma concentrations are achieved rapidly after injection.
Metabolism
Minimally metabolized; primarily excreted unchanged.
Side Effects
Contraindications
- •Active intravascular clotting (DIC)
- •Hypersensitivity to aminocaproic acid
- •Severe renal impairment
- •Upper urinary tract bleeding (risk of obstruction from clots)
Drug Interactions
Oral Contraceptives/Estrogens
Increased risk of thrombosis.
Factor IX Complex Concentrates
Potential for increased thrombotic complications.
Anticoagulants (e.g., Heparin, Warfarin)
Concomitant use may theoretically counteract the effects of both drugs, but generally not recommended due to increased risk of clotting.
Storage
Store at controlled room temperature (20-25°C), protect from light. Do not freeze.
Overdose
Symptoms of overdose may include hypotension, bradycardia, confusion, seizures, renal impairment, and myopathy with rhabdomyolysis. Management is supportive, including careful monitoring of vital signs and renal function, and discontinuation of the drug. Dialysis may be considered for severe cases.
Pregnancy & Lactation
Pregnancy Category C. Use only if clearly needed and the potential benefits outweigh the potential risks to the fetus. Excreted into breast milk; caution advised in nursing mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, when stored under recommended conditions.
Availability
Available in hospitals and pharmacies
Approval Status
Approved
Patent Status
Off-patent
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in